


I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office, Fax No. 1-703-872-9306 on December 29, 2003.

TOWNSEND and TOWNSEND and CREW LLP

By: 

PATENT

Attorney Docket No.: 015270-008930US
Client Reference No.: 334-US-NEW3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

DEC 29 2003

**RECEIVED
CENTRAL FAX CENTER
OFFICIAL**

In re application of:

Dale B. Schenk et al.

Application No.: 10/698,099

Filed: October 31, 2003

For: PREVENTION AND TREATMENT
OF SYNUCLEINOPATHIC DISEASE

Examiner: Unassigned

Art Unit: Unassigned

**INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The reference cited on the attached PTO/SB/08A form is being called to the attention of the Examiner. Pursuant to the Official Gazette Notice of 05 August 2003 a copy of the reference is not enclosed. It is respectfully requested that the cited reference be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.


As provided for by 37 CFR 1.97(g) and (h), no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information, and no inference should be made that the information and references cited are, or are considered to be material to patentability because they are in this statement. No inference should be made that the information and references cited are prior art merely because they are in this statement.

Dale B. Schenk et al.
Application No.: Unassigned
Page 2

PATENT

Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Rosemarie L. Celli

Reg. No. 42,397

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 650-326-2400
Fax: 650-326-2422
RLC
60109485 v1

Substitute for form 1449A/PTO				<i>Complete If Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	Unassigned
(use as many sheets as necessary)				Filing Date	October 31, 2003
				First Named Inventor	Schenk, Dale B.
				Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	1	of	1	Attorney Docket Number	015270-008930US

U.S. PATENT DOCUMENTS*					
		Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Page, Column, Line, Where Relevant Passages or Relevant Figures Appear
Examiner Initials*	Cite No.*	Number Kind Code ² (If Known)	12-26-2002	Ghanbari et al.	
	AA	2002/0197258 A1			

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbol as indicated on the document under WIPO Standard ST. 1B. If possible, ⁶ Applicant is to place a check mark here if English language Translation is attached.